• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Illumina, One of My Short Stock Candidates, Shows Mediocre Growth

ILMN shares were down about 15% in Friday trading after they pre-announced a revenue miss for its second quarter.
By JIM COLLINS
Jul 12, 2019 | 02:01 PM EDT
Stocks quotes in this article: ILMN, TSLA, NOW, ISRG, WDAY, NFLX, SQ, PLD, HNHPF

One down, eight to go. I mentioned nine individual stocks as short candidates in my RM column yesterday, and Illumina (ILMN) was the first to answer the call. ILMN shares plunged 16% in this morning's trading after the company pre-announced a revenue miss for its second quarter after the close of trading last night. ILMN expects 2Q19 revenues of $835 million, well below the Street consensus estimate of $888 million and a truly anemic growth rate versus 2Q18's reported revenues of $830 million. ILMN management did not mention a profit impact from the slower than expected revenues. One has to assume it will be significant, though, especially since ILMN management noted:

"In light of the Company's lower revenue growth expectations for 2019, Illumina is taking immediate action to adjust operating expenses for the remainder of the year."

So, that's a clear sign of a profit warning in a business that is clearly slowing. ILMN CEO Francis deSouza blamed the miss on transitory issues, but we veteran stock analysts know much better than that. I once had a buy-side client tell me that earnings warnings are like roaches. You see one, but you know there are more to follow.

But, Illumina's pre-pre-annnouncement market cap of $52 billion seemingly priced in zero chance of an earnings miss. And that's the problem with individual stocks in a market that is rolling to yet another new all-time high in today's trading. "Priced for perfection" is an old cliche about highly valued stocks, but that doesn't even begin to capture what is going on in certain sectors of the U.S. stock market. These stocks are priced for fantasy, not perfection. That's a big difference, and, as my new venture, Excelsior Capital Partners, emerges from its current "soft open" phase, I will implement to short positions in wildly overvalued stocks.

As mentioned yesterday, I will keep all numbers generated by screens I run for Excelsior as proprietary data, but I am willing to share some of the categories I use. Illumina was one of the most highly valued names in Bloomberg's U.S stock universe in the categories of trailing EV/sales, forward EV/EBITDA, and forward (next 12 months) P/E. Other than that it looked pretty cheap to me.

Seriously, though, Illumina is now forecasting 6% revenue growth for this year, yet, as of yesterday, was trading at more than 52x forward EPS. Did your head just explode after reading that? If you are a value investor, or any type of investor, you realize a PEG ratio 8.5 times is just bananas. But that's what this market was giving Illumina. 'Was' being the operative word.

It's one thing to place a stratospheric multiple on high growth, but to place such a multiple on mediocre growth is truly nonsensical. It is also expensive for those who are invested in names that fit that profile, as Illumina clearly did.

So, as a reminder, here are the nine names I mentioned in yesterday's column. Paperwork issues (soon I will begin publicly naming the brokerage that is slowing me down) may be slowing the launch of Excelsior's short portfolio, but Excelsior's' guiding principle - cash flow never lies - is in full effect as evidenced by ILMN's downfall. Earnings pre-announcements - colloquially known among analysts as "confession season" - are fun, but that joy pales in comparison to the stock volatility driven by earnings announcements themselves. Earnings season begins in earnest next week. I cannot wait.

Tesla (TSLA)

ServiceNow (NOW)

Illumina ILMN

Intuitive Surgical (ISRG)

Workday (WDAY)

Netflix (NFLX)

Square (SQ)

Prologis (PLD)

Hon Hai (HNHPF)

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Jim Collins had no position in the securities mentioned.

TAGS: Short-selling | Investing | Stocks | Trading | Biotechnology

More from Investing

Don't Shout 'V' for Victory, Yet

James "Rev Shark" DePorre
Jun 27, 2022 4:22 PM EDT

Even after last week's move higher and Monday's narrow range of movement, we can say it's going to be difficult to produce a 'V'-shaped setup like we had at the pandemic low in 2020.

Let's See If Vertex Pharmaceuticals Can Push Higher on the Charts

Bruce Kamich
Jun 27, 2022 3:03 PM EDT

Here's what traders should do.

LyondellBasell Could Hold Temporarily Before Renewed Declines

Bruce Kamich
Jun 27, 2022 2:22 PM EDT

Let's take a look.

Kass: Why Markets Could Make a Yankees-Like Comeback

Doug Kass
Jun 27, 2022 2:00 PM EDT

I remain uncharacteristically bullish. Here's why.

Here's How to Treat Bristol-Myers Squibb's Charts

Bruce Kamich
Jun 27, 2022 1:10 PM EDT

BMY is breaking out to a new high.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 12:04 AM EDT PAUL PRICE

    Two Good Signs -- Especially for Small-Cap Investors

  • 12:10 AM EDT PAUL PRICE

    More Insider Buying in American Woodmark (AMWD)

    American Woodmark , which I've discussed here fr...
  • 08:55 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    The 10 personality traits of successful traders an...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login